The Effects of Vitamin D Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

摘要

Data on the effects of vitamin D supplementation on metabolic status of patients with polycystic ovary syndrome (PCOS) are scarce. The current study was conducted to evaluate the effects of vitamin D supplementation on metabolic status of patients with PCOS. This randomized double-blind, placebo-controlled trial was performed on 70 vitamin D-deficient (serum concentrations < 20 ng/ml) women with phenotype B-PCOS according to the Rotterdam criteria aged 18-40 years old. Participants were randomly allocated into 2 groups to take either 50 000 IU vitamin D (n = 35) or placebo (n = 35) every 2 weeks for 12 weeks. Metabolic, endocrine, inflammation, and oxidative stress biomarkers were quantified at the beginning of the study and after 12-week intervention. After the 12-week intervention, compared to the placebo, vitamin D supplementation significantly decreased fasting plasma glucose (FPG) (-3.1 +/- 7.3 vs. + 0.5 +/- 6.3 mg/dl, p = 0.02), insulin (-1.4 +/- 3.6 vs. + 2.6 +/- 7.0 mu IU/ml, p = 0.004), homeostasis model of assessment-estimated insulin resistance (-0.3 +/- 0.8 vs. + 0.6 +/- 1.6, p = 0.003), homeostasis model of assessment-estimated B cell function (-4.9 +/- 13.4 vs. + 9.9 +/- 26.9, p = 0.005), and increased quantitative insulin sensitivity check index (+ 0.01 +/- 0.01 vs.-0.02 +/- 0.05, p = 0.007). Supplementation with vitamin D also led to significant reductions in serum high-sensitivity C-reactive protein (hs-CRP) (-0.7 +/- 1.4 vs. + 0.5 +/- 2.1 mu g/mL, p = 0.009) and plasma malondialdehyde (MDA) levels (-0.1 +/- 0.5 vs. + 0.9 +/- 2.1 mu mol/l, p = 0.01) compared to the placebo. Overall, vitamin D supplementation for 12 weeks in vitamin D-deficient women with phenotype B-PCOS had beneficial effects on glucose homeostasis parameters, hs-CRP, and MDA.